IDDM
MCID: DBT085
MIFTS: 72

Diabetes Mellitus, Insulin-Dependent (IDDM)

Categories: Endocrine diseases, Genetic diseases, Metabolic diseases, Rare diseases

Aliases & Classifications for Diabetes Mellitus, Insulin-Dependent

MalaCards integrated aliases for Diabetes Mellitus, Insulin-Dependent:

Name: Diabetes Mellitus, Insulin-Dependent 57 25 75 38 40 73
Type 1 Diabetes Mellitus 38 12 25 37 15
Diabetes Mellitus Type 1 76 53 25 29 6
Iddm 57 12 53 25 75
Insulin-Dependent Diabetes Mellitus 12 53 25
Juvenile-Onset Diabetes 57 53 25
Type 1 Diabetes 53 25 63
Diabetes Mellitus, Insulin-Dependent, Susceptibility to 13 6
Diabetes Mellitus, Insulin-Dependent-1 57 13
Diabetes Mellitus, Type 1 25 44
Type I Diabetes Mellitus 12 6
Jod 57 25
Diabetes Mellitus, Type 1, Susceptibility to 6
Diabetes Mellitus, Insulin Dependent 53
Diabetes Mellitus Insulin-Dependent 55
Juvenile-Onset Diabetes Mellitus 25
Juvenile-Onset Diabetes; Jod 57
Diabetes, Insulin Dependent 76
Diabetes Mellitus, Type I 57
Diabetes, Autoimmune 73
Autoimmune Diabetes 25
Diabetes Autoimmune 55
Juvenile Diabetes 25
Diabetes Type 1 43
Type I Diabetes 15
T1d 25

Characteristics:

OMIM:

57
Inheritance:
heterogeneous
autosomal recessive susceptibility


HPO:

32
diabetes mellitus, insulin-dependent:
Inheritance heterogeneous


Classifications:



Summaries for Diabetes Mellitus, Insulin-Dependent

PubMed Health : 63 About type 1 diabetes: Diabetes is a metabolic disease that affects many parts of the body. Depending on the type of diabetes, the body either cannot produce insulin itself (type 1) or is unable to use the insulin it produces properly (type 2). Insulin is a hormone – a chemical messenger that is transported in the blood and regulates important body functions. Without insulin your body cannot get the energy it needs from the food you have eaten.This vital hormone is usually produced in the pancreas and released into the bloodstream. Here it enables the sugar (glucose) in our food and drink to be transported into our cells and converted into energy for our bodies. Without insulin our bodies cannot use the sugar in our blood, so the sugar builds up there. Very high blood sugar concentrations cause a number of symptoms.People with type 1 diabetes have to inject insulin on a daily basis because their pancreas can only produce insulin in very small quantities, or can’t produce any insulin at all. Insulin therapy helps prevent strong fluctuations in blood sugar levels and the unpleasant effects of high and low blood sugar. It is also intended to prevent complications that may arise as a result of high blood sugar levels.

MalaCards based summary : Diabetes Mellitus, Insulin-Dependent, also known as type 1 diabetes mellitus, is related to diabetes mellitus, insulin-dependent, 23 and type 1 diabetes mellitus 2, and has symptoms including polydipsia and polyuria. An important gene associated with Diabetes Mellitus, Insulin-Dependent is HNF1A (HNF1 Homeobox A), and among its related pathways/superpathways are Type I diabetes mellitus and T cell receptor signaling pathway. The drugs Zinc and Saxagliptin have been mentioned in the context of this disorder. Affiliated tissues include Bone and Pancreas, and related phenotypes are diabetes mellitus and polydipsia

Disease Ontology : 12 A diabetes mellitus that results from the body's failure to produce insulin and has material basis in autoimmune destruction of insulin-producing beta cells of the pancreas.

Genetics Home Reference : 25 Type 1 diabetes is a disorder characterized by abnormally high blood sugar levels. In this form of diabetes, specialized cells in the pancreas called beta cells stop producing insulin. Insulin controls how much glucose (a type of sugar) is passed from the blood into cells for conversion to energy. Lack of insulin results in the inability to use glucose for energy or to control the amount of sugar in the blood.

NIH Rare Diseases : 53 Diabetes mellitus type 1 (DM1) is a condition in which cells in the pancreas (beta cells) stop producing insulin, causing abnormally high blood sugar levels. Lack of insulin results in the inability of the body to use glucose for energy and control the amount of sugar in the blood. DM1 can occur at any age, but usually develops by early adulthood, most often in adolescence. Symptoms of high blood sugar may include frequent urination, excessive thirst, fatigue, blurred vision, tingling or loss of feeling in the hands and feet, and weight loss. The exact cause of DM1 is unknown, but having certain "variants" of specific genes may increase a person's risk to develop the condition. A predisposition to develop DM1 runs in families, but no known inheritance pattern exists. Treatment includes blood sugar control and insulin replacement therapy. Improper control can cause recurrence of high blood sugar, or abnormally low blood sugar (hypoglycemia) during exercise or when eating is delayed. If not treated, the condition can be life-threatening. Over many years, chronic high blood sugar may be associated with a variety of complications that affect many parts of the body.

OMIM : 57 The type of diabetes mellitus called IDDM is a disorder of glucose homeostasis that is characterized by susceptibility to ketoacidosis in the absence of insulin therapy. It is a genetically heterogeneous autoimmune disease affecting about 0.3% of Caucasian populations (Todd, 1990). Genetic studies of IDDM have focused on the identification of loci associated with increased susceptibility to this multifactorial phenotype. The classical phenotype of diabetes mellitus is polydipsia, polyphagia, and polyuria which result from hyperglycemia-induced osmotic diuresis and secondary thirst. These derangements result in long-term complications that affect the eyes, kidneys, nerves, and blood vessels. (222100)

MedlinePlus : 43 Diabetes means your blood glucose, or blood sugar, levels are too high. With type 1 diabetes, your pancreas does not make insulin. Insulin is a hormone that helps glucose get into your cells to give them energy. Without insulin, too much glucose stays in your blood. Over time, high blood glucose can lead to serious problems with your heart, eyes, kidneys, nerves, and gums and teeth. Type 1 diabetes happens most often in children and young adults but can appear at any age. Symptoms may include Being very thirsty Urinating often Feeling very hungry or tired Losing weight without trying Having sores that heal slowly Having dry, itchy skin Losing the feeling in your feet or having tingling in your feet Having blurry eyesight A blood test can show if you have diabetes. If you do, you will need to take insulin for the rest of your life. A blood test called the A1C can check to see how well you are managing your diabetes. NIH: National Institute of Diabetes and Digestive and Kidney Diseases

UniProtKB/Swiss-Prot : 75 Diabetes mellitus, insulin-dependent: A multifactorial disorder of glucose homeostasis that is characterized by susceptibility to ketoacidosis in the absence of insulin therapy. Clinical features are polydipsia, polyphagia and polyuria which result from hyperglycemia-induced osmotic diuresis and secondary thirst. These derangements result in long-term complications that affect the eyes, kidneys, nerves, and blood vessels.

Wikipedia : 76 Diabetes mellitus type�1, also known as type 1 diabetes, is a form of diabetes mellitus in which very... more...

Related Diseases for Diabetes Mellitus, Insulin-Dependent

Diseases in the Diabetes Mellitus, Insulin-Dependent family:

Diabetes Mellitus, Insulin-Dependent, 2 Diabetes Mellitus, Insulin-Dependent, 3
Diabetes Mellitus, Insulin-Dependent, 4 Diabetes Mellitus, Insulin-Dependent, 5
Diabetes Mellitus, Insulin-Dependent, 7 Diabetes Mellitus, Insulin-Dependent, 8
Diabetes Mellitus, Insulin-Dependent, 11 Diabetes Mellitus, Insulin-Dependent, 13
Diabetes Mellitus, Insulin-Dependent, 12 Diabetes Mellitus, Insulin-Dependent, 15
Diabetes Mellitus, Insulin-Dependent, 6 Diabetes Mellitus, Insulin-Dependent, 10
Diabetes Mellitus, Insulin-Dependent, 17 Diabetes Mellitus, Insulin-Dependent, 18
Diabetes Mellitus, Insulin-Dependent, 19 Diabetes Mellitus, Insulin-Dependent, 20
Diabetes Mellitus, Insulin-Dependent, 21 Diabetes Mellitus, Insulin-Dependent, 22
Diabetes Mellitus, Insulin-Dependent, 23 Diabetes Mellitus, Insulin-Dependent, 24

Diseases related to Diabetes Mellitus, Insulin-Dependent via text searches within MalaCards or GeneCards Suite gene sharing:

(show top 50) (show all 643)
# Related Disease Score Top Affiliating Genes
1 diabetes mellitus, insulin-dependent, 23 34.7 IDDM23 INS
2 type 1 diabetes mellitus 2 33.3 INS PTPN22
3 type 1 diabetes mellitus 11 33.3 HNF1A INS
4 maturity-onset diabetes of the young, type 1 32.5 HNF1A IL6 INS
5 diabetes mellitus 31.2 FOXP3 HNF1A IL6 INS MEG3 PTPN22
6 autoimmune disease 31.0 FOXP3 IL6 INS PTPN22
7 microvascular complications of diabetes 3 30.9 INS PVT1
8 alpha/beta t-cell lymphopenia with gamma/delta t-cell expansion, severe cytomegalovirus infection, and autoimmunity 30.8 FOXP3 INS PTPN22
9 pancreatic endocrine carcinoma 30.5 INS MEG3
10 maturity-onset diabetes of the young, type 2 30.2 HNF1A INS
11 coronary heart disease 1 30.1 IGF2-AS IL6 INS
12 cerebrovascular disease 30.0 IL6 INS MEG3
13 maturity-onset diabetes of the young, type 3 29.7 HNF1A INS
14 diabetes mellitus, insulin-dependent, 20 13.0
15 diabetes mellitus, insulin-dependent, 22 12.9
16 diabetes mellitus, insulin-dependent, 19 12.9
17 diabetes mellitus, insulin-dependent, 10 12.9
18 diabetes mellitus, insulin-dependent, 2 12.8
19 diabetes mellitus, insulin-dependent, 5 12.8
20 diabetes mellitus, insulin-dependent, 12 12.8
21 diabetes mellitus, insulin-dependent, 21 12.7
22 diabetes mellitus, insulin-dependent, 24 12.7
23 diabetes mellitus, insulin-dependent, x-linked 12.6
24 diabetes mellitus, insulin-dependent, 7 12.6
25 diabetes mellitus, insulin-dependent, 8 12.6
26 diabetes mellitus, insulin-dependent, 13 12.6
27 diabetes mellitus, insulin-dependent, 3 12.5
28 diabetes mellitus, insulin-dependent, 4 12.5
29 diabetes mellitus, insulin-dependent, 11 12.5
30 diabetes mellitus, insulin-dependent, 15 12.5
31 diabetes mellitus, insulin-dependent, 6 12.5
32 diabetes mellitus, insulin-dependent, 17 12.5
33 diabetes mellitus, insulin-dependent, 18 12.5
34 histiocytosis-lymphadenopathy plus syndrome 12.5
35 type 1 diabetes mellitus 3 11.8
36 type 1 diabetes mellitus 4 11.8
37 type 1 diabetes mellitus 5 11.8
38 type 1 diabetes mellitus 6 11.8
39 type 1 diabetes mellitus 7 11.8
40 type 1 diabetes mellitus 8 11.8
41 type 1 diabetes mellitus 10 11.8
42 type 1 diabetes mellitus 12 11.8
43 type 1 diabetes mellitus 13 11.8
44 type 1 diabetes mellitus 15 11.8
45 type 1 diabetes mellitus 17 11.8
46 type 1 diabetes mellitus 18 11.8
47 ataxia, combined cerebellar and peripheral, with hearing loss and diabetes mellitus 11.8
48 diabetes mellitus, noninsulin-dependent, 1 11.8
49 brittle diabetes 11.5
50 pancreatic beta cell agenesis with neonatal diabetes mellitus 11.5

Graphical network of the top 20 diseases related to Diabetes Mellitus, Insulin-Dependent:



Diseases related to Diabetes Mellitus, Insulin-Dependent

Symptoms & Phenotypes for Diabetes Mellitus, Insulin-Dependent

Symptoms via clinical synopsis from OMIM:

57
Endocrine:
diabetes mellitus

Lab:
hyperglycemia
relative insulin deficiency

G U:
polyuria
hyperglycemia-induced osmotic diuresis

G I:
polydipsia
polyphagia

Metabolic:
ketoacidosis
abnormally increased gluconeogenesis
insufficient glucose disposal

Immunology:
pancreatic autoimmunity


Clinical features from OMIM:

222100

Human phenotypes related to Diabetes Mellitus, Insulin-Dependent:

32 (show all 8)
# Description HPO Frequency HPO Source Accession
1 diabetes mellitus 32 HP:0000819
2 polydipsia 32 HP:0001959
3 autoimmunity 32 HP:0002960
4 polyphagia 32 HP:0002591
5 hyperglycemia 32 HP:0003074
6 ketoacidosis 32 HP:0001993
7 polyuria 32 HP:0000103
8 decreased level of 1,5 anhydroglucitol in serum 32 HP:0410050

UMLS symptoms related to Diabetes Mellitus, Insulin-Dependent:


polydipsia, polyuria

Drugs & Therapeutics for Diabetes Mellitus, Insulin-Dependent

PubMedHealth treatment related to Diabetes Mellitus, Insulin-Dependent: 63

In type 1 diabetes, the focus of treatment is to monitor blood sugar levels every day and regularly use insulin. Insulin therapy makes up for the lack of insulin in the body and lowers the concentration of sugar in the blood. It is important to avoid using too much or too little insulin, to prevent blood sugar levels from getting too low or too high. Treatment also aims to prevent long-term complications associated with diabetes as much as possible. There are different types of insulin and different treatment approaches.Blood sugar levels are not only affected by the amount of insulin you inject but also by what you eat and drink, as well as how much energy you use during physical activity. The time of day, inflammatory diseases, other medications or hormonal changes can influence your blood sugar levels too. So most people learn to finely adjust their insulin therapy according to their own body and personal habits.In order for treatment to be successful, people need to be well informed about their diabetes, manage their own therapy and have reliable medical care. But over the long term, your general health will depend on other things besides just blood sugar levels. Aspects like blood pressure can have a big effect in diabetes. Because of this, people with diabetes often take other medications as well, for example to prevent cardiovascular disease.

Drugs for Diabetes Mellitus, Insulin-Dependent (from DrugBank, HMDB, Dgidb, PharmGKB, IUPHAR, NovoSeek, BitterDB):

(show top 50) (show all 620)
# Name Status Phase Clinical Trials Cas Number PubChem Id
1
Zinc Approved, Investigational Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable,Early Phase 1 7440-66-6
2
Saxagliptin Approved Phase 4,Phase 3,Phase 2 361442-04-8 11243969
3
Insulin Detemir Approved Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable 169148-63-4 5311023
4
Insulin Glargine Approved Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable,Early Phase 1 160337-95-1
5
Pancrelipase Approved, Investigational Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable,Early Phase 1 53608-75-6
6
rituximab Approved Phase 4,Phase 1,Phase 2 174722-31-7 10201696
7
Insulin Aspart Approved Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable 116094-23-6 16132418
8
Insulin Lispro Approved Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable,Early Phase 1 133107-64-9
9
Insulin glulisine Approved Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable 207748-29-6
10
Diazoxide Approved Phase 4 364-98-7 3019
11
Exenatide Approved, Investigational Phase 4,Phase 2,Phase 3,Phase 1,Not Applicable 141758-74-9 15991534
12
Glyburide Approved Phase 4,Phase 2,Phase 3 10238-21-8 3488
13
Angiotensin II Approved, Investigational Phase 4,Phase 3,Phase 2,Not Applicable 11128-99-7, 68521-88-0, 4474-91-3 172198 65143
14
Candesartan cilexetil Approved Phase 4,Phase 3,Not Applicable 145040-37-5 2540
15
Hydrocortisone Approved, Vet_approved Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable 50-23-7 5754
16
Hydrocortisone acetate Approved, Vet_approved Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable 50-03-3
17
Liraglutide Approved Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable,Early Phase 1 204656-20-2 44147092
18
Metformin Approved Phase 4,Phase 2,Phase 3,Not Applicable,Early Phase 1 657-24-9 14219 4091
19
Nitric Oxide Approved Phase 4,Not Applicable 10102-43-9 145068
20
Ethanol Approved Phase 4,Phase 2,Phase 1,Not Applicable,Early Phase 1 64-17-5 702
21
Vildagliptin Approved, Investigational Phase 4,Phase 3,Phase 2 274901-16-5 6918537
22
Rosiglitazone Approved, Investigational Phase 4,Not Applicable 122320-73-4 77999
23
Tacrolimus Approved, Investigational Phase 4,Phase 3,Phase 1,Phase 2,Not Applicable 104987-11-3 445643 439492
24
Mycophenolic acid Approved Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable 24280-93-1 446541
25
Sirolimus Approved, Investigational Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable 53123-88-9 46835353 6436030 5284616
26
Miconazole Approved, Investigational, Vet_approved Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable 22916-47-8 4189
27
Everolimus Approved Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable 159351-69-6 6442177
28
Pramlintide Approved, Investigational Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable 151126-32-8
29
Aspirin Approved, Vet_approved Phase 4,Phase 2 50-78-2 2244
30
Nitroglycerin Approved, Investigational Phase 4,Not Applicable 55-63-0 4510
31
Febuxostat Approved Phase 4 144060-53-7 134018
32
Regadenoson Approved, Investigational Phase 4 313348-27-5 219024
33
Adenosine Approved, Investigational Phase 4 58-61-7 60961
34
Allopurinol Approved Phase 4,Phase 3 315-30-0 2094
35
Spironolactone Approved Phase 4,Not Applicable 52-01-7, 1952-01-7 5833
36
Tocopherol Approved, Investigational Phase 4,Phase 3,Phase 1,Not Applicable 1406-66-2 14986
37
Guaifenesin Approved, Investigational, Vet_approved Phase 4 93-14-1 3516
38
Norepinephrine Approved Phase 4,Not Applicable 51-41-2 439260
39
Midazolam Approved, Illicit Phase 4 59467-70-8 4192
40
Tramadol Approved, Investigational Phase 4 27203-92-5 33741
41
Metoprolol Approved, Investigational Phase 4 37350-58-6, 51384-51-1 4171
42
Gliclazide Approved Phase 4 21187-98-4 3475
43
alemtuzumab Approved, Investigational Phase 4,Phase 1,Phase 2 216503-57-0
44
Promethazine Approved, Investigational Phase 4 60-87-7 4927
45
Dexamethasone acetate Approved, Investigational, Vet_approved Phase 4,Phase 1,Not Applicable 1177-87-3
46
Dexamethasone Approved, Investigational, Vet_approved Phase 4,Phase 1,Not Applicable 50-02-2 5743
47
Heparin Approved, Investigational Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable 9005-49-6 772 46507594
48
Diphenhydramine Approved, Investigational Phase 4 147-24-0, 58-73-1 3100
49
Acetaminophen Approved Phase 4,Phase 2,Phase 1,Not Applicable 103-90-2 1983
50
Empagliflozin Approved Phase 4,Phase 3,Phase 2,Not Applicable 864070-44-0

Interventional clinical trials:

(show top 50) (show all 2509)
# Name Status NCT ID Phase Drugs
1 The Effect of Saxagliptin on Glucose Fluctuation and Immune Regulation in Patients With Type 1 Diabetes Unknown status NCT02307695 Phase 4 Saxagliptin;Insulin
2 Comparing Long-acting Insulins During Exercise in Type 1 Diabetes Unknown status NCT01440439 Phase 4 Insulin glargine;Insulin detemir
3 Mixed Meal Test in Type 1 Diabetes: Optimization of Artificial Pancreas-Pilot Study Unknown status NCT01800734 Phase 4
4 Probiotics in Newly Recognized Type 1 Diabetes Unknown status NCT03032354 Phase 4 Lactobacillus rhamnosus GG and Bifidobacterium lactis BB12
5 Immune Intervention With Rituximab to Preserve Beta Cell Function in Early Onset Type 1 Diabetes Unknown status NCT01280682 Phase 4 rituximab
6 Treatment of Low Blood Sugar With Glucagon Among Patients With Type 1 Diabetes Unknown status NCT02232971 Phase 4 Glucagon
7 Insulin Requirement for Pure-protein Meal in Children With Type 1 Diabetes on Insulin Pumps. Unknown status NCT02685449 Phase 4 Insulin glulisine;Insulin aspart;Insulin lispro
8 Basal Analog Study - Comparison of Lantus or Levemir With NPH Insulin From T1DM Diagnosis Unknown status NCT01271517 Phase 4 NPH insulin;Glargine;Detemir
9 Use of Diazoxide in Acute Hypoglycaemia Unknown status NCT01488136 Phase 4 Diazoxide;Placebo
10 An Investigation Into the Effect of Dapagliflozin on Ketogenesis in Type 1 Diabetes Unknown status NCT02962492 Phase 4 Exenatide/Exenatide extended release;Dapagliflozin;Placebo
11 Dapagliflozin in Type 1 Diabetes Unknown status NCT02211742 Phase 4 Dapagliflozin
12 Real-Time Continuous Glucose Monitoring in Pre-School Children With Type-1 Diabetes Mellitus Unknown status NCT01016457 Phase 4
13 A Crossover Study With Hexalacton in Patients With Type 1 Diabetes and Microalbuminuria Unknown status NCT00843388 Phase 4 Spironolacton (hexalacton(R));placebo tablet
14 Do Sulphonylureas Preserve Cortical Function During Hypoglycaemia? Unknown status NCT00472875 Phase 4 Glibenclamide
15 Diabetes Type 1, Treatment Study Atacand/Placebo After Kidney Biopsy Unknown status NCT00328302 Phase 4 Candesartan;Placebo
16 Insulin NovoRapid Versus Actrapid in Treatment of Type 1 Diabetic Patients During Daily Adjustment of Insulin Dose Unknown status NCT00145353 Phase 4 Insulin NovoRapid versus Actrapid
17 GLP-1 Analogue Treatment in Uncontrolled Type 1 Diabetic Patients Unknown status NCT01592279 Phase 4 liraglutide;Insulin injections
18 Vitamin D and Glucose Metabolism in Pediatrics Unknown status NCT01386736 Phase 4 Vitamin D drops;Placebo drops
19 Association of Type 1 Diabetes Mellitus in Offsprings With Positive Parental History of Diabetes Completed NCT03312478 Phase 4 Blood draw for insulin auto-anti body tests*
20 Study to Estimate the Effects of Inhaled Versus Intravenous (IV) Infusion of Human Insulin in Subjects With Type 1 Diabetes Completed NCT00315952 Phase 4 Exubera
21 Clinical Trial of Efficiency and Safety of Subetta in the Combined Treatment of Patients With Type I Diabetes Mellitus Completed NCT01868594 Phase 4 Subetta;Placebo
22 Assessing Glucose Effects of Sitagliptin (Januvia) in Adult Patients With Type 1 Diabetes Completed NCT00978796 Phase 4 Sitagliptin;Sugar Pill
23 52 Week Trial of Liraglutide in Type 1 Diabetes Completed NCT01787916 Phase 4 Liraglutide;Placebos
24 Comparison Between GLP 1 Analogues and DPP 4 Inhibitors in Type 1 Diabetes Mellitus Completed NCT01235819 Phase 4 Insulin;Sitagliptin;Exenatide
25 Diabetes Care Management Compared to Standard Diabetes Care in Adolescents and Young Adults With Type 1 Diabetes Completed NCT01351857 Phase 4
26 Pilot Study of the GlucoWatch G2 Biographer for the Management of Type 1 Diabetes in Children Completed NCT00069615 Phase 4
27 Liraglutide in Type 1 Diabetes Completed NCT01612468 Phase 4 Liraglutide;Placebo
28 Use of Exenatide and Pramlintide to Decrease Post-prandial Hyperglycemia Completed NCT01269047 Phase 4 Pramlintide;Exenatide;Insulin
29 Efficacy of Diazoxide in Type 1 Diabetes Completed NCT00131755 Phase 4 diazoxide
30 Post-meal Insulin Dosing With Adjuvant Pre-meal Pramlintide in Children With Type 1 Diabetes Mellitus Completed NCT00442767 Phase 4 Insulin;Pramlintide + Insulin
31 A Pilot Study to Assess the Glucose Lowering Effect of Metformin and Sitagliptin in Adolescents With Type 1 Diabetes Completed NCT01718093 Phase 4 Sitagliptin;Metformin;Sitagliptin + Metformin
32 Effects of Aspirin Treatment on Fibrin Network Formation in Patients With Type 1 Diabetes Completed NCT01397513 Phase 4 Aspirin
33 Effects of Vitamin D Supplementation in Subjects With New Onset of Type 1 Diabetes Completed NCT01390480 Phase 4 Cholecalciferol
34 The Effect of Uric Acid Lowering in Type 1 Diabetes Completed NCT02344602 Phase 4 Febuxostat
35 Role of Mobile Technology to Improve Diabetes Care in Adults With Type 1 Diabetes: the REMOTE-T1D Study, a Pilot Study Completed NCT01825382 Phase 4
36 Sitagliptin Dose Determination Study Completed NCT01530178 Phase 4 Sitagliptin;Placebo Oral Tablet
37 The Effect of Supplementation With Two Different Doses of Vitamin D on Bone Mineral Density, Vitamin D Levels and Hand Grip Strength in Children With Diabetes Mellitus Type 1 Completed NCT01277913 Phase 4 Vitamin D3;Vitamin D3
38 Insulin Glulisine and Aspart in Postprandial Glycemic Control After High-GI Meal in Children With Type 1 Diabetes Mellitus Completed NCT01678235 Phase 4 Insulin glulisine;Insulin aspart
39 Metabolic Effects of Accurate Blood Sugar Results and Education in Type 1 Diabetes Completed NCT00284232 Phase 4 Insulin dosing based on SMBG chart and education
40 A Study Comparing the Efficacy and Safety of the Morning Injection of Toujeo Versus Lantus in Patients With Type 1 Diabetes Mellitus Completed NCT02688933 Phase 4 HOE901-U300 (Insulin Glargine 300 U/ml);Lantus (Insulin Glargine 100 U/ml);Mandated back ground therapy
41 Detemir: Role in Type 1 Diabetes Completed NCT00564395 Phase 4 Insulin Detemir mixed with RAI injection;Insulin Detemir and RAI injection
42 Effect of Metformin in Patients With Type-1 Diabetes With Inadequate Glycaemic Control by Insulin and Diet Completed NCT00118937 Phase 4 Metformin;Placebo.;Placebo.
43 Treatment Trial Evaluating Long Acting Insulin in Type 1 Diabetes Completed NCT00276393 Phase 4 Basal insulin
44 Test of the Efficacy and Safety of Insulin Glulisine Injected Subcutaneously in Patients With Type 1 Diabetes Mellitus Completed NCT00964574 Phase 4 INSULIN GLULISINE (HMR1964);INSULIN GLARGINE
45 Prevention of Severe Hypoglycemia in Type 1 Diabetes Completed NCT00360984 Phase 4 insulin glargine
46 Randomized Clinical Trial to Assess the Effectiveness of the GlucoWatch Biographer Completed NCT00069628 Phase 4
47 Continuous Glucose Monitors for Children With Diabetes Mellitus Completed NCT00069537 Phase 4
48 Safety and Efficacy of Insulin Aspart in Children With Type 1 Diabetes Completed NCT01467141 Phase 4 insulin aspart;human insulin;isophane human insulin
49 A Study of Continuous Subcutaneous Insulin Infusion (CSII) Pump Function in Subjects With Type 1 Diabetes With Recombinant Human Hyaluronidase (rHuPH20) Completed NCT03662334 Phase 4 Rapid Acting insulin with pre-treatment of rHuPH20
50 Human Insulin NPH and Insulin Aspart in Type 1 Diabetes Completed NCT00597233 Phase 4 insulin aspart;soluble human insulin;insulin NPH

Search NIH Clinical Center for Diabetes Mellitus, Insulin-Dependent

Inferred drug relations via UMLS 73 / NDF-RT 51 :


Cell-based therapeutics:


LifeMap Discovery
Data from LifeMap, the Embryonic Development and Stem Cells Database
Read about Diabetes Mellitus, Insulin-Dependent cell therapies at LifeMap Discovery.
Stem-cell-based therapeutic approaches for Diabetes Mellitus, Insulin-Dependent:
Bone marrow-derived adult mesenchymal stem cells for treatment of type I diabetes
Bone marrow-derived mononuclear cells for the treatment of diabetes mellitus
Dendritic cells for type I diabetes
Dental pulp stem cell-derived islet clusters for treating diabetes
DIABECELL�, insulin-producing cells for type 1 diabetes
Encapsulated embryonic stem cell-derived NKX6.1-positive cells for diabetes
Encapsulated embryonic stem cell-derived pancreatic progenitor cells for treatment of diabetes
Endothelial progenitor cell and islet cotransplantation for diabetes
Fibroblast-derived pancreatic progenitor cells for treatment of diabetes
Hematopoietic stem cell transplantation for new-onset type 1 diabetes
Hematopoietic stem cells for early-onset type I diabetes mellitus
Hematopoietic stem cells for treatment of early-onset type I diabetes mellitus
Hematopoietic stem cells for type I diabetes mellitus
Human islet transplantation to treat diabetes
Porcine embryonic pancreatic tissue transplantation for diabetes
Prochymal�, mesenchymal stem cells for treatment of type 1 diabetes mellitus
Regulatory T cells for type I diabetes
Stem cell-derived pancreatic islets for diabetes treatment
StemGenex�, adipose-derived stem cells for diabetes
Umbilical cord-derived mesenchymal stem cells for treatment of type I diabetes
VC-01, embryonic stem cell-derived pancreatic progenitor cells for treatment of diabetes
Embryonic/Adult Cultured Cells Related to Diabetes Mellitus, Insulin-Dependent:
Bone marrow-derived mesenchymal stem cells (family)
Bone marrow-derived mononuclear cells (family)
Immunosuppressive dendritic cells PMIDs: 17665986 18552749 23148758
Mouse immunosuppressive dendritic cells PMIDs: 17665986 18552749 23148758
Islet-like cell clusters PMIDs: 23845187
Encapsulated neonatal porcine islets (DIABECELL�) PMIDs: 15808678 18814261 17607741 21358330 21535153 16131605 23088180 19063691 16298643 11202575 17381690
Pancreatic endoderm and endocrine precursors in cell suspension
Pancreatic endoderm/endocrine precursor-like cells PMIDs: 24788136 20587750 18834446 22623968 18034635
Mouse Islets PMIDs: 22362173
Umbilical cord blood-derived endothelial progenitor cells PMIDs: 22362173
Pancreatic islets PMIDs: 22362173
Pancreatic progenitor-like cells PMIDs: 24506886
Peripheral blood-derived hematopoietic stem cells (family) PMIDs: 23190701
Peripheral blood-derived hematopoietic stem cells PMIDs: 23190701
Peripheral blood-derived hematopoietic stem cells PMIDs: 23190701
Bone marrow-derived hematopoietic stem cells (family)
Pancreatic islets (cadavers) PMIDs: 15983207 10911004
Fetal pancreatic tissue PMIDs: 16768546 19433788
Regulatory T cells PMIDs: 15322272 16903917
Islet-like structures PMIDs: 24268157
Adipose-derived stem cells (StemGenex�)
Wharton-Jelly-derived mesenchymal stem cells

Cochrane evidence based reviews: diabetes mellitus, type 1

Genetic Tests for Diabetes Mellitus, Insulin-Dependent

Genetic tests related to Diabetes Mellitus, Insulin-Dependent:

# Genetic test Affiliating Genes
1 Diabetes Mellitus Type 1 29 FOXP3 HNF1A IL6 ITPR3 PTPN22

Anatomical Context for Diabetes Mellitus, Insulin-Dependent

MalaCards organs/tissues related to Diabetes Mellitus, Insulin-Dependent:

41
Pancreas, Kidney, Bone, Testes, Eye, T Cells, Skin
LifeMap Discovery
Data from LifeMap, the Embryonic Development and Stem Cells Database

Cells/anatomical compartments in embryo or adult related to Diabetes Mellitus, Insulin-Dependent:
# Tissue Anatomical CompartmentCell Relevance
1 Bone Bone Marrow Bone Marrow Stromal Cells Potential therapeutic candidate
2 Pancreas Islets of Langerhans Mature Beta Cells Affected by disease, potential therapeutic candidate
3 Umbilical Cord Wharton's Jelly Mesenchymal Stem Cells Potential therapeutic candidate
4 Blood Cord Blood Mesenchymal Stem Cells Potential therapeutic candidate
5 Adipose Subcutaneous White Adipose Mesenchymal Stem Cells Potential therapeutic candidate
6 Adipose Subcutaneous White Adipose Stromal Cells Potential therapeutic candidate

Publications for Diabetes Mellitus, Insulin-Dependent

Articles related to Diabetes Mellitus, Insulin-Dependent:

(show top 50) (show all 843)
# Title Authors Year
1
Glutamine and type 1 diabetes mellitus: is there a role in glycemic control? ( 30461450 )
2019
2
Acute-onset Autoimmune Hepatitis in a Young Woman with Type 1 Diabetes Mellitus. ( 29321432 )
2018
3
Cataract as Early Ocular Complication in Children and Adolescents with Type 1 Diabetes Mellitus. ( 29755521 )
2018
4
The Influence of Type 1 Diabetes Mellitus on Dental Caries and Salivary Composition. ( 30369949 )
2018
5
Assessment of dental caries and gingival status among a group of type 1 diabetes mellitus and healthy children of South India - a comparative study. ( 30465719 )
2018
6
Type 1 Diabetes Mellitus-Associated Genetic Variants Contribute to Overlapping Immune Regulatory Networks. ( 30524468 )
2018
7
Pulmonary mucormycosis in an adolescent female with type 1 diabetes mellitus. ( 30524955 )
2018
8
Impaired pressure natriuresis and non-dipping blood pressure in Rats with early type 1 diabetes mellitus. ( 30537108 )
2018
9
Stem cell transplantation for the treatment of patients with type 1 diabetes mellitus: A meta-analysis. ( 30542397 )
2018
10
Depressive symptoms and cerebral microvascular disease in adults with Type 1 diabetes mellitus. ( 30552772 )
2018
11
Practice Variance in Thyroid Screening of Youth with Type 1 Diabetes Mellitus. ( 30497072 )
2018
12
Insulin protects against hepatocyte ultrastructural damage induced by type 1 diabetes mellitus in rats. ( 30497321 )
2018
13
Acute hypoglycemia during cesarean delivery in a patient with Type-1 diabetes mellitus. ( 30503204 )
2018
14
Dietary vitamin and mineral intakes in a sample of pregnant women with either gestational diabetes or type 1 diabetes mellitus, assessed in comparison with Polish nutritional guidelines. ( 30508208 )
2018
15
Empagliflozin on top of metformin treatment improves arterial function in patients with type 1 diabetes mellitus. ( 30509271 )
2018
16
Status and trends in the use of insulin analogs, insulin delivery systems and their association with glycemic control: comparison of the two consecutive recent cohorts of Japanese children and adolescents with type 1 diabetes mellitus. ( 30517078 )
2018
17
CD19+IgM+ cells demonstrate enhanced therapeutic efficacy in type 1 diabetes mellitus. ( 30518692 )
2018
18
Differential effects of type 1 diabetes mellitus and subsequent osteoblastic β-catenin activation on trabecular and cortical bone in a mouse model. ( 30518745 )
2018
19
Nivolumab-induced acute-onset type 1 diabetes mellitus as an immune-related adverse event: A case report. ( 30526346 )
2018
20
Perioperative management in a patient with type 1 diabetes mellitus who presented severe hypoglycemia during dental implant surgery: a case report. ( 30526578 )
2018
21
The Association of CEP135 rs4865047 and NPY2R rs1902491 Single Nucleotide Polymorphisms (SNPs) with Rapid Progression of Proliferative Diabetic Retinopathy in Patients with Type 1 Diabetes Mellitus. ( 30531682 )
2018
22
Insulin pump settings and glucose patterns during a 1008-km non-stop bicycle race in a patient with type 1 diabetes mellitus. ( 30443779 )
2018
23
Association between proprotein convertase subtilisin/kexin 9 (PCSK9) and lipoprotein subclasses in children with type 1 diabetes mellitus: Effects of glycemic control. ( 30453116 )
2018
24
Bilateral Posterior Circulation Stroke in a Child with Type 1 Diabetes Mellitus. ( 30453356 )
2018
25
Cochlear dysfunction and microvascular complications in patients with type 1 diabetes mellitus. ( 30455746 )
2018
26
Peripheral body temperature impairment in individuals with type 1 diabetes mellitus. ( 30455844 )
2018
27
Urinary glucose excretion after dapagliflozin treatment: An exposure-response modelling comparison between Japanese and non-Japanese patients diagnosed with type 1 diabetes mellitus. ( 30456904 )
2018
28
Clinical and socio-demographic determinants of inadequate self-care in adults with type 1 diabetes mellitus: the leading role of self-care confidence. ( 30478783 )
2018
29
Maturity Onset Diabetes of the Young due to Glucokinase, HNF1-A, HNF1-B, and HNF4-A Mutations in a Cohort of Turkish Children Diagnosed as Type 1 Diabetes Mellitus. ( 30481753 )
2018
30
Relationship between bullying and type 1 diabetes mellitus in children and adolescents: a systematic review. ( 30391140 )
2018
31
Detection of occult right ventricular dysfunction in young Egyptians with type 1 diabetes mellitus by two-dimensional speckle tracking echocardiography. ( 30392504 )
2018
32
Urine Levels of Matrix Metalloproteinases and Tissue Inhibitor of Metalloproteinases in Children with Type 1 Diabetes Mellitus. ( 30396876 )
2018
33
Exercise modes and their association with hypoglycemia episodes in adults with type 1 diabetes mellitus: a systematic review. ( 30397494 )
2018
34
Association between Early Neuroretinal Dysfunction and Peripheral Motor Unit Loss in Patients with Type 1 Diabetes Mellitus. ( 30402503 )
2018
35
Clinical Pharmacology of Fast-Acting Insulin Aspart Versus Insulin Aspart Measured as Free or Total Insulin Aspart and the Relation to Anti-Insulin Aspart Antibody Levels in Subjects with Type 1 Diabetes Mellitus. ( 30402720 )
2018
36
Comparison of proinsulin and C-peptide secretion in healthy versus long-standing type 1 diabetes mellitus cohorts: A pilot study. ( 30412637 )
2018
37
Type 1 diabetes mellitus prevalence and care in children under 15 years old in Asturias. ( 30413391 )
2018
38
Evolving Pharmacotherapeutic Strategies for Type 1 Diabetes Mellitus. ( 30429688 )
2018
39
A multicentre, UK, retrospective, observational study to assess the effectiveness of insulin glargine 300 units/ml in treating people with Type 1 diabetes mellitus in routine clinical practice (SPARTA). ( 30362181 )
2018
40
Variables to Be Monitored via Biomedical Sensors for Complete Type 1 Diabetes Mellitus Management: An Extension of the "On-Board" Concept. ( 30363935 )
2018
41
High Risk of Deep Neck Infection in Patients with Type 1 Diabetes Mellitus: A Nationwide Population-Based Cohort Study. ( 30366374 )
2018
42
Gene therapy and type 1 diabetes mellitus. ( 30372820 )
2018
43
The association between Type 1 diabetes mellitus and periodontal diseases. ( 30391109 )
2018
44
Low hemoglobin A1c levels in a patient with diabetic ketoacidosis: Fulminant type 1 diabetes mellitus. ( 30325130 )
2018
45
Firing Up Glycolysis: BCG Vaccination Effects on Type 1 Diabetes Mellitus. ( 30327169 )
2018
46
Bilateral cataracts as the first manifestation of type 1 diabetes mellitus: A case report. ( 30335004 )
2018
47
Classical HLA alleles tag SNP in families from Antioquia with type 1 diabetes mellitus ( 30335238 )
2018
48
Psychological stress and type 1 diabetes mellitus: what is the link? ( 30336709 )
2018
49
Familial aggregation and heritability of type 1 diabetes mellitus and coaggregation of chronic diseases in affected families. ( 30349392 )
2018
50
Low doses of dasiglucagon consistently increase plasma glucose levels from hypoglycaemia and euglycaemia in people with type 1 diabetes mellitus. ( 30350477 )
2018